The impact of inhibiting SHP-2 in myeloid cells has been previously reported by using allosteric inhibitors of SHP-2 such as SHP099, TNO155 (ref. 48) and RMC4550 (ref. 49) to target cancer cells where SHP-2 is activated downstream of RTK/Ras signaling and functions as an oncogene. This evidence concerns the gene PTPN11 and cancer.